Pursuant to Regulation 34 of SEBI Listing Regulations, please find enclosed the Notice of 18th Annual General Meeting to be held on Tuesday, 22/September/2026.

SUDARSHAN PHARMA INDUSTRIES LTD Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092. E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997 SPIL/CS/SE/2026-2027/54 Date: 29th August, 2026 The Listing Department BSE Scrip Code: 543828 BSE Limited BSE Trading Symbol: SUDARSHAN Phiroze Jeejeebhoy Towers, ISIN: INE00TV01023 Dalal Street, Mumbai – 400 001 Dear Sir / Madam, Sub: Notice of 18th Annual General Meeting ----------------------------------------------------------------------------------------------------------------- Dear Sir / Madam, Pursuant to Regula(cid:415)on 34 of the SEBI (Lis(cid:415)ng Obliga(cid:415)ons And Disclosure Requirements) Regula(cid:415)ons, 2015, please find enclosed the No(cid:415)ce of 18th Annual General Mee(cid:415)ng (‘AGM’) to be held on Tuesday, 22nd September 2026 at 3.00 p.m. IST through Video Conferencing / Other Audio Visual Means. Pursuant to circulars issued by the Ministry of Corporate Affairs and Securi(cid:415)es and Exchange Board of India, the Annual Report for Financial Year 2025-26 is being sent electronically to all the members of the Company whose email addresses are registered with the Company / Depository Par(cid:415)cipants. Kindly take the same on record. Yours truly, For, Sudarshan Pharma Industries Limited Nirav Shah Company Secretary & Compliance Officer Encl: As above Regd. Off.: 301, Aura Biplex, Above Kalyan Jewellers, S.V. Road, Borivali (West), Mumbai - 400092. SUDARSHAN Sudarshan Pharma Industries Limited NOTICE Notice is hereby given that the 18th Annual General Meeting of the members of Sudarshan Pharma Industries Limited (“the Company”) will be held on Tuesday, 22nd day of September, 2026 at 3:00 p.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) to transact the following business as: Ordinary Business: 1. To receive, consider and adopt the audited financial statements (including the consolidated financial statements) of the Company for the financial year ended 31st March, 2026 together with the Reports of the Board of Directors and the Auditors thereon. 2. To appoint a director in place of Dr. Anil Ghogare (DIN - 00432659), who retires by rotation and being eligible, offers himself for re-appointment. “Resolved that, in accordance with the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, Dr. Anil Ghogare (DIN - 00432659), who retires by rotation at this Annual General Meeting, and being eligible for re-appointment, be and is hereby appointed as a Director of the Company.” D S By Order of the Board of Directors Sudarshan Pharma Industries Limited Hemal Mehta Date: 12th August 2026 Chairman & Managing Director Place: Mumbai DIN: 02211121 Annual Report 2025-26 43 SUDARSHAN Sudarshan Pharma Industries Limited ADDITIONAL INFORMATION ON DIRECTOR SEEKING RE-APPOINTMENT AT THE 18th ANNUAL GENERAL MEETING (Pursuant to Regulation 36 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard 2 issued by the Institute of Company Secretaries of India) Name of the Director Dr. Anil Ghogare DIN 00432659 Designation / Category of the Director Non-Executive Non-Independent Director Age 17th June 1960 (65 years) Date of Appointment / applicable date of first 10th November 2023 appointment on the Board Educational Qualification Masters of Business Administration (M.B.A.), Finance from M. S. University, Baroda Ph.D. in Pharmaceutical Chemistry, Mumbai University. Masters of Technology (M. Tech), Chemical & A RInstrumentation, Indian Institute of Technology (IIT), New D DelS hi. Masters of Science (M. SC). in Organic Chemistry, Pune S University. Brief Profile/ Experience and Expertise in specific 37 years of Nexperience in Fermentation Technology as Functional Area well as Advisor and Directors in various pharmaceutical companies, GMP / Regulatory consultant for design of plant, technology transfers and regulatory support. Terms and Conditions of appointment Appointed as Non-Executive Non-Independent Director liable to retire by rotation Remuneration last drawn Nil Shareholding in the Company including shareholding Nil as a beneficial owner Relationship with other directors and KMPs of the Not related with any director or key managerial personnel Company of the Company No. of Meetings of Board attended during the 7 (Seven) Financial Year Name of Listed Companies in which hold Directorship Nil (excluding this entity) Name of listed entities from which the person has Nil resigned in the past three years Chairman / Member of the Committees Nil of Board of Directors of Indian Companies In the case of independent directors, the skills and Not Applicable capabilities required for the role and the manner in which the proposed person meets such requirements 44 Annual Report 2025-26 SUDARSHAN Sudarshan Pharma Industries Limited NOTES 1. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (the “Act”) setting out material facts concerning the business under item nos. 3 to 6 of the Notice is annexed hereto. The relevant details pursuant to Regulations 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Directors seeking re-appointment at this Annual General Meeting (“AGM”) are also annexed. 2. In view of circulars issued by the Ministry of Corporate Affairs (“MCA”) vide General Circular nos. 14/2020, 17/2020, 39/2020, 20/2021, 3/2022, 09/2023, 09/2024 and 03/2025 dated April 8, 2020, April 13, 2020, December 31, 2020, December 8, 2021, May 5, 2022, September 25, 2023, September 19, 2024 and September 22, 2025 respectively, the forthcoming AGM will be held through video conferencing (‘VC’) or other audio visual means (‘OAVM’). Hence, members can attend and participate in the ensuing AGM through VC / OAVM. 3. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI Listing Regulations and MCA General Circulars dated April 08, 2020 and April 13, 2020, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (“NSDL”) for facilitating voting through electronic means, as the authorized agency. The facilitDy of castingS votes by a member using remote e-Voting system as well as venue voting on the date of the AUGM will be provided by NSDL. 4. The Members can join the AGM in VSC / OAVM mode 15 minutes before and after the scheduled time of the commencement of the AGM by following the procedure mentioneNd in the Notice. The facility of participation at the AGM through VC / OAVM will be made available to at least 1000 members on first-come-first-serve basis. This will not include large shareholders (shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination & Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first-come-first-serve basis. 5. The attendance of the Members attending the AGM through VC / OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013. 6. Since the AGM is being convened through VC / OAVM and accordingly, the route map of the venue of the AGM is not annexed hereto. 7. Pursuant to MCA General Circular No. 14/2020 dated April 08, 2020 and MCA General Circular No. 17/2020 dated April 13, 2020, the facilit [Showing first 8,000 characters — download PDF for full document]